What are the management options for an adult patient experiencing weight gain potentially related to hormonal imbalances, such as hypothyroidism, Cushing's syndrome, or polycystic ovary syndrome (PCOS)?

Hormonal Causes of Weight Gain and Management Strategies

When to Test for Hormonal Causes

Screen for hormonal causes of weight gain only when specific clinical features suggest endocrine dysfunction—not in all patients with obesity. 1, 2

Specific Indications for Hormone Testing

• Menstrual irregularities: Cycles <23 days or >35 days, or amenorrhea >6 months warrant testing 1
• Hyperandrogenism signs: Hirsutism, acne, or male-pattern hair loss suggest PCOS or other androgen excess 1
• Infertility: Inability to conceive after 12 months of unprotected intercourse 1
• Galactorrhea: Nipple discharge may indicate hyperprolactinemia 1
• Central obesity with menstrual disturbance: Waist-to-hip ratio >0.9 combined with irregular periods 1
• Weight gain with growth deceleration: In children/adolescents, unexplained weight gain combined with decreased height velocity or height standard deviation score is highly specific for Cushing syndrome 3
• Rapid weight gain with specific features: Central fat distribution, proximal muscle weakness, wide violaceous striae (>1 cm), or easy bruising suggest Cushing syndrome 3

Red Flags Requiring Immediate Evaluation

• Early-onset obesity with hyperphagia: Especially with developmental delay, dysmorphic features, or striking family history suggests monogenic obesity 4
• Resistant hypertension with weight gain: Consider primary aldosteronism or Cushing syndrome 3
• Cold intolerance, constipation, dry skin: Classic hypothyroidism symptoms 3

Comprehensive Hormone Panel When Testing is Indicated

Order a targeted panel based on clinical suspicion rather than blanket testing. 1, 2

Core Hormone Tests

• TSH: Screen for hypothyroidism; levels >2 mIU/L may be abnormal in PCOS context 1
• LH and FSH: LH/FSH ratio >2 suggests PCOS; FSH >35 IU/L indicates premature ovarian failure 1
• Total testosterone: Levels >2.5 nmol/L suggest PCOS or hyperandrogenic states 1
• Prolactin: Morning resting samples >20 μg/L are abnormal; levels >4,000 mU/L (>80 μg/L) require immediate endocrinology referral 1
• Mid-luteal progesterone: Levels <6 nmol/L indicate anovulation common in PCOS 1

Additional Metabolic Testing

• Fasting glucose and insulin: Glucose/insulin ratio >4 suggests reduced insulin sensitivity 1
• 24-hour urinary free cortisol: Three consecutive collections with levels >193 nmol/24 h (>70 μg/m²) suggest Cushing syndrome 3
• Overnight dexamethasone suppression test: Serum cortisol >50 nmol/L (>1.8 μg/dL) after 1 mg dexamethasone at midnight has the greatest specificity for Cushing syndrome 3, 5
• Late-night salivary cortisol: Based on local assay cut-offs, has 95% sensitivity and 100% specificity for Cushing syndrome 3

Management of Specific Hormonal Conditions

Polycystic Ovary Syndrome (PCOS)

Weight loss of just 5-10% can restore ovulation, improve fertility, and reduce cardiovascular and endometrial cancer risk in PCOS. 3

First-Line Lifestyle Interventions

• Exercise prescription: 150+ minutes per week of moderate activity OR 75+ minutes of vigorous activity; for weight loss, increase to 300+ minutes per week moderate OR 150+ minutes vigorous 3
• Resistance training: Include weight training 2 times per week for weight maintenance, or more frequently for weight loss 3
• Dietary modifications: Create 500-750 kcal/day energy deficit through portion control and elimination of ultraprocessed foods 6
• Target moderate-to-high intensity: 70-90% of maximum heart rate (calculated as 220 minus age) 3

Pharmacotherapy for PCOS-Related Weight Management

• Metformin 1000 mg daily: Results in mean weight reduction of 3.27 kg (95% CI: -4.66 to -1.89 kg) and improves insulin sensitivity 6
• GLP-1 receptor agonists: Semaglutide or liraglutide produce 14.9-16% mean weight loss when combined with lifestyle changes 6
• Dual GIP/GLP-1 agonist: Tirzepatide is emerging as highly effective option 6

Critical Pitfall to Avoid

Eating disorders (binge eating disorder, night eating syndrome) are significantly more prevalent in PCOS and create a vicious cycle worsening both obesity and hormonal disturbances. 3 Address psychological factors including emotional stress related to hirsutism, infertility, and insulin resistance, as untreated emotional eating will undermine weight management efforts 3

Hypothyroidism

Screen with TSH in patients with cold intolerance, constipation, weight gain, dry skin, or delayed ankle reflexes. 3

• Confirm with free thyroxine if TSH is abnormal 3
• Thyroid hormone replacement typically reverses weight gain associated with hypothyroidism 7, 8
• Mechanism: Hypothyroidism causes fluid retention from reduced cardiac output, accumulation of hyaluronic acid in tissues, and reduced thermogenesis 7

Cushing Syndrome

Use the 1-mg overnight dexamethasone suppression test as the most specific screening tool, especially in women with PCOS where urinary free cortisol may be falsely elevated. 3, 5

Diagnostic Algorithm

1. First-line screening: Overnight 1-mg dexamethasone suppression test (cortisol >138 nmol/L has greatest specificity) OR late-night salivary cortisol OR 24-hour urinary free cortisol (three collections) 3, 5
2. Confirm ACTH-dependency: Normal or elevated 09:00 h plasma ACTH supports Cushing disease 3
3. Imaging: Pituitary MRI for suspected Cushing disease; adrenal CT for ACTH-independent disease 3

Key Clinical Features

• Central obesity with moon face, dorsal and supraclavicular fat pads 3
• Wide violaceous striae (>1 cm), not the thin striae of simple obesity 3
• Proximal muscle weakness, easy bruising, depression, hyperglycemia 3
• In children: Weight gain with growth failure (height SDS below mean while BMI SDS above mean) is highly sensitive and specific 3

Medication-Induced Weight Gain

Identify and address contributing medications, particularly psychiatric drugs, corticosteroids, insulin, and specific beta-blockers. 4

Management of Valproate-Induced Weight Gain

• First choice: Switch to weight-neutral alternatives (lamotrigine, levetiracetam) if seizure control permits 6
• Adjunctive topiramate: 100 mg/day produces mean weight reduction of 3.76 kg (95% CI: -4.92 to -2.69 kg) 6
• Adjunctive metformin: 1000 mg daily produces mean weight reduction of 3.27 kg (95% CI: -4.66 to -1.89 kg) 6
• Monitoring: Monthly weight checks for first 3 months, then quarterly; intervene if >2 kg gain in first month or ≥7% increase from baseline 6

When to Refer to Endocrinology

Refer for specialist evaluation in the following scenarios: 1

• Persistent abnormal hormone levels despite initial management 1
• Prolactin >4,000 mU/L (>80 μg/L) 1
• Pituitary abnormality on MRI 1
• Markedly elevated DHEAS suggesting adrenal pathology or non-classical congenital adrenal hyperplasia 1
• Confirmed Cushing syndrome requiring specialized treatment 3
• Monogenic or syndromic obesity with early onset, hyperphagia, developmental delay, or dysmorphic features 4

Critical Pitfalls to Avoid

• Do not perform blanket endocrine testing in all patients with obesity—this leads to false positives and unnecessary interventions 2
• Do not use urinary free cortisol alone in women with PCOS, as it has lower specificity than dexamethasone suppression test in this population 5
• Do not overlook reversible causes before initiating hormone replacement: address depression, pain, constipation, sleep disorders, and medication side effects first 4
• Do not ignore socioeconomic barriers to treatment: only 20% of insured adults have coverage for anti-obesity medications like semaglutide, with disproportionate impact on Hispanic (29.3% uninsured) and Black (14.7% uninsured) populations 3
• Do not use corticosteroids long-term for appetite stimulation due to muscle wasting, insulin resistance, and osteopenia 9